Nadav Kidron

I raised the money, started the company.

And 13 years later, we are at a very advanced stage and we are seeing now the last steps in order to get it into registration.

There's no such a thing as definitely happening because it's not up to me.

At the end of the day, you have the FDA that they called the shot.

So I can never say it's definitely coming.

At the end of the day, the advantage that we have is that unlike a new drug, I come to New York and say, wow, listen, I find this new chemical entity and that can help diabetes.

Here, what we do is we're taking insulin that has been around for a long time and we know that it works.

And we have the ability to deliver it orally instead of an injection that we already proved in principle that that works.

So that's why I think while there's still a risk.

the chances by our technology is much higher than something which is totally new.

For most chances, it's going to be one of the two, meaning most chances it will be successful and big.

or nothing.

I'm talking generally in the industry.

In our case, I think the chances of success are a little bit better because, like I said, we've got the principle there.

But sometimes you get a situation where something works, it's not that exciting, so it's going to be a drug that's not going to sell for a billion dollars, but maybe there's a $50 million market or you find a niche that you can plug yourself into.

But 90% chance, when you look at our industry, it's you make it or you break it.

So we ourselves, we have a pipeline.

We have other things beyond insulin.

So we're working on insulin.

We're working on another drug that's called GLP-1 analog.